Reviewer's report

Title: Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death

Version: 3 Date: 7 June 2011

Reviewer: David Church

Reviewer's report:

The authors have responded satisfactorily to almost all the comments made. However, the principal point has still not been addressed; the title and abstract wording suggest impact of trastuzumab after brain metastases were diagnosed while the actual analysis is of trastuzumab treatment at any stage during the disease course. Providing the abstract wording is amended to make this clear I am happy for this to be accepted for publication.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have previously received travel expenses and honoraria from Roche.
I have no other competing interests